Skip to main content

Free Content Bioavailability of rifampicin in Indonesian subjects: a comparison of different local drug manufacturers

Download Article:
 Download
(PDF 139.375 kb)
 
To examine the bioavailability of rifampicin formulations produced in Indonesia, we conducted a single-dose, double-blind, cross-over bioavailability study. Anti-tuberculosis drugs from three Indonesian manufacturers and one international manufacturer were compared in 12 healthy Indonesian subjects. Out of three local manufacturers, two showed equal bioavailability compared to the reference standard, and one showed slightly lower bioavailability (ratio 0.86; 90% confidence interval 0.80–0.91) and substandard rifampicin content of drug preparations. Plasma rifampicin concentrations in this study were more than three-fold higher than concentrations recently found in tuberculosis patients in Indonesia, which suggests that unknown (disease-related) determinants may reduce the bioavailability of rifampicin formulations.
No References
No Citations
No Supplementary Data
No Article Media
No Metrics

Keywords: Indonesia; biological bioavailability; formulation; rifampicin; tuberculosis treatment

Document Type: Short Communication

Affiliations: 1: Department of Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands 2: Working Group on Infectious Diseases, Faculty of Medicine, University of Indonesia, Jakarta, Indonesia 3: Eijkman Institute for Molecular Biology, Jakarta, Indonesia 4: Department of Clinical Pharmacy, University Medical Center Nijmegen, Nijmegen, The Netherlands 5: Department of Internal Medicine, University Medical Center Nijmegen, Nijmegen, The Netherlands; and Department of Internal Medicine, Padjadjaran University, Bandung, Indonesia 6: Department of Pulmonology, University Medical Center Nijmegen, Nijmegen, The Netherlands

Publication date: 2004-04-01

More about this publication?
  • The International Journal of Tuberculosis and Lung Disease publishes articles on all aspects of lung health, including public health-related issues such as training programmes, cost-benefit analysis, legislation, epidemiology, intervention studies and health systems research. The IJTLD is dedicated to the continuing education of physicians and health personnel and the dissemination of information on tuberculosis and lung health world-wide.

    Certain IJTLD articles are selected for translation into French, Spanish, Chinese or Russian. They are available on the Union website

  • Editorial Board
  • Information for Authors
  • Subscribe to this Title
  • International Journal of Tuberculosis and Lung Disease
  • Public Health Action
  • Ingenta Connect is not responsible for the content or availability of external websites
  • Access Key
  • Free content
  • Partial Free content
  • New content
  • Open access content
  • Partial Open access content
  • Subscribed content
  • Partial Subscribed content
  • Free trial content
Cookie Policy
X
Cookie Policy
Ingenta Connect website makes use of cookies so as to keep track of data that you have filled in. I am Happy with this Find out more